Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

P. P. Tak; P. J. Mease; M. C. Genovese; J. Kremer; B. Haraoui; Y. Tanaka; C. O. Bingham; A. Ashrafzadeh; H. Travers; S. Safa-Leathers; S. Kumar; W. Dummer

doi:10.1002/art.33353

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

Arthritis & Rheumatism ◽

10.1002/art.33353 ◽

2012 ◽

Vol 64 (2) ◽

pp. 360-370 ◽

Cited By ~ 41

Author(s):

P. P. Tak ◽

P. J. Mease ◽

M. C. Genovese ◽

J. Kremer ◽

B. Haraoui ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Inhibitor ◽

Phase Iii ◽

Inadequate Response ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Parallel Group ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Arthritis & Rheumatism ◽

10.1002/art.22025 ◽

2006 ◽

Vol 54 (9) ◽

pp. 2793-2806 ◽

Cited By ~ 1041

Author(s):

Stanley B. Cohen ◽

Paul Emery ◽

Maria W. Greenwald ◽

Maxime Dougados ◽

Richard A. Furie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734268130.793576219 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718325315.793492809 ◽

2014 ◽

Author(s):

Ronald van Vollenhoven

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

Critical Care Medicine ◽

10.1097/00003246-200103000-00006 ◽

2001 ◽

Vol 29 (3) ◽

pp. 503-510 ◽

Cited By ~ 205

Author(s):

Edward Abraham ◽

Pierre-François Laterre ◽

Jorge Garbino ◽

Susan Pingleton ◽

Thomas Butler ◽

...

Keyword(s):

Septic Shock ◽

Severe Sepsis ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Receptor ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase ◽

Necrosis Factor

Download Full-text

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

Arthritis & Rheumatism ◽

10.1002/art.33317 ◽

2012 ◽

Vol 64 (2) ◽

pp. 350-359 ◽

Cited By ~ 42

Author(s):

W. Rigby ◽

H.-P. Tony ◽

K. Oelke ◽

B. Combe ◽

A. Laster ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Phase Iii ◽

Inadequate Response ◽

Double Blind ◽

Phase Iii Trial ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Parallel Group

Download Full-text

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Arthritis & Rheumatology ◽

10.1002/art.40753 ◽

2019 ◽

Vol 71 (4) ◽

pp. 599-611 ◽

Cited By ~ 54

Author(s):

Atul Deodhar ◽

Denis Poddubnyy ◽

Cesar Pacheco‐Tena ◽

Carlo Salvarani ◽

Eric Lespessailles ◽

...

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies

Rheumatology International ◽

10.1007/s00296-009-0845-3 ◽

2009 ◽

Vol 29 (11) ◽

pp. 1287-1291 ◽

Cited By ~ 19

Author(s):

Taio Naniwa ◽

Maiko Watanabe ◽

Shogo Banno ◽

Tomoyo Maeda

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Low Dose ◽

Tumor Necrosis Factor Inhibitor ◽

Inadequate Response ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Ustekinumab in active psoriatic arthritis including patients previously treated with anti–tumor necrosis factor agents: Week 24 results from PSUMMIT 2, a phase III, multicenter, double-blind, placebo-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2012.12.895 ◽

2013 ◽

Vol 68 (4) ◽

pp. AB217

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Previously Treated ◽

Necrosis Factor

Download Full-text

A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate

APLAR Journal of Rheumatology ◽

10.1111/j.1479-8077.2007.00248.x ◽

2007 ◽

Vol 10 (1) ◽

pp. 9-16 ◽

Cited By ~ 38

Author(s):

Ho-Youn KIM ◽

Soo-Kon LEE ◽

Yeong Wook SONG ◽

Dae-Hyun YOO ◽

Eun-Mi KOH ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Phase Iii ◽

Double Blind ◽

Subcutaneous Injections ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Necrosis Factor

Download Full-text

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Arthritis & Rheumatology ◽

10.1002/art.38851 ◽

2014 ◽

Vol 66 (12) ◽

pp. 3255-3264 ◽

Cited By ~ 66

Author(s):

Michael E. Weinblatt ◽

Mark C. Genovese ◽

Meilien Ho ◽

Sally Hollis ◽

Krystyna Rosiak-Jedrychowicz ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Phase Iii ◽

Inadequate Response ◽

Spleen Tyrosine Kinase ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

Download Full-text